- Home
- GIPR vs APLM Comparison
GIPR vs APLM Comparison
Compare GIPR & APLM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GIPR
- APLM
- Stock Information
- Founded
- GIPR 2015
- APLM 2016
- Country
- GIPR United States
- APLM United States
- Employees
- GIPR N/A
- APLM N/A
- Industry
- GIPR Real Estate Investment Trusts
- APLM Blank Checks
- Sector
- GIPR Real Estate
- APLM Finance
- Exchange
- GIPR Nasdaq
- APLM Nasdaq
- Market Cap
- GIPR 5.1M
- APLM 6.1M
- IPO Year
- GIPR 2021
- APLM N/A
- Fundamental
- Price
- GIPR $1.09
- APLM $18.43
- Analyst Decision
- GIPR
- APLM
- Analyst Count
- GIPR 0
- APLM 0
- Target Price
- GIPR N/A
- APLM N/A
- AVG Volume (30 Days)
- GIPR 569.9K
- APLM 88.1K
- Earning Date
- GIPR 11-14-2025
- APLM 09-30-2025
- Dividend Yield
- GIPR N/A
- APLM N/A
- EPS Growth
- GIPR N/A
- APLM N/A
- EPS
- GIPR N/A
- APLM N/A
- Revenue
- GIPR $9,884,093.00
- APLM $198,000.00
- Revenue This Year
- GIPR $1.12
- APLM $415.15
- Revenue Next Year
- GIPR $0.52
- APLM N/A
- P/E Ratio
- GIPR N/A
- APLM N/A
- Revenue Growth
- GIPR 2.33
- APLM N/A
- 52 Week Low
- GIPR $0.78
- APLM $3.66
- 52 Week High
- GIPR $2.44
- APLM $35.98
- Technical
- Relative Strength Index (RSI)
- GIPR 56.88
- APLM 90.29
- Support Level
- GIPR $0.88
- APLM $3.66
- Resistance Level
- GIPR $1.18
- APLM $6.37
- Average True Range (ATR)
- GIPR 0.12
- APLM 1.65
- MACD
- GIPR 0.03
- APLM 1.20
- Stochastic Oscillator
- GIPR 33.87
- APLM 85.30
About GIPR Generation Income Properties Inc.
Generation Income Properties Inc is an internally managed real estate investment company focused on acquiring and managing income-producing retail, office and industrial properties net leased to high-quality tenants in markets throughout the United States. Its key source of revenue is the rental income. The company holds properties in Alabama, Arizona, Colorado, the District of Columbia, Florida, Illinois, North Carolina and Virginia.
About APLM Apollomics Inc.
Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.